Spyre Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Spyre Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$0
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$209.56M	-$208.57M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$155.20M	-$208.02M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-160.02	$-257.60
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-160.02	$-257.60

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$85.72M	$89.42M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$777.78M	$608.48M
Everything the company owes — debt, unpaid bills, and other obligations.	$62.55M	$90.68M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$715.24M	$517.80M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$169.25M	-$157.41M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	$0
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	-$157.41M